Hybrigenics SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Hybrigenics SA's inecalcitol is designated as an orphan drug for chronic lymphocytic leukemia in Europe
Hybrigenics SA:Announces the decision of the European Commission to designate inecalcitol as an orphan drug for the treatment of chronic lymphocytic leukemia (CLL), following the positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency.Says Inecalcitol is listed in the Community Register of designated Orphan Medicinal Products under the entry code EU/3/13/1223.
Latest Developments forHybrigenics SA
- Hybrigenics raises total of 9 million euros in capital increase
- Hybrigenics SA inecalcitol gets Orphan Drug designation for treatment of Chronic Lymphocytic Leukemia in United States
- Hybrigenics launches Helixio, its new branch dedicated to genomic services
- Hybrigenics SA raises 6.1 million euros in private placement and reserved capital increase
Latest Key Developments inBiotechnology
- Share this
- Digg this